ESSA Pharma in the spotlight (part II)
Q2 business update overview and next steps
Essa (EPIX) reported their Q2 business update this morning. The rumors were true – Phase 1 monotherapy data will be pushed from 2H 2021 to 1H 2022. This is not a good sign because patient data in higher cohorts has been collected for >6 months, since February 2021. Not sharing this data in the near term implies it is not as expected.
Patients are curre…